JW Holdings Corporation (096760) AI Stock Analysis

• Market Cap: ₩271.92B
• Dividend Yield: 5.47%
• Average Volume (3M): 58.82K
• Price to Earnings (P/E): 3.2
• Beta (1Y): 0.17
• Revenue Growth: 10.18%
• EPS Growth: 149.93%
• Country: KR
• Employees: 128
• Sector: General
• Sector Strength: N/A
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 1218.54
• Shares Outstanding: 73,924,940
• 10 Day Avg. Volume: 55,034
• 30 Day Avg. Volume: 58,820
• PEG Ratio: -1.12
• Price to Book (P/B): 0.94
• Price to Sales (P/S): 0.26
• P/FCF Ratio: 1.86
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 72 Outperform
• Price Target: ₩4,335.00
• Action: N/A
• Date: 10/28/26

Positive Factors

Improved Profitability

The shift to consistently positive earnings and an improved net margin indicates stronger profitability than in earlier years. Stable gross margins around 49–50% provide a durable base for earnings resilience, helping the group retain more revenue as profit across its healthcare-related businesses.

Negative Factors

Above-Average Leverage

Debt remains high relative to equity, leaving the company more exposed to financing pressure than a lightly leveraged balance sheet would be. Although equity rebuilding has improved the position, leverage can constrain strategic flexibility and partially amplify reported returns such as the approximately 31% TTM ROE.

JW Holdings Corporation Business Overview & Revenue Model

Company Description

JW Holdings Corporation, alongside its numerous subsidiaries, is a key player in the manufacturing and commercialization of pharmaceuticals and medical devices. Its operations span South Korea and global markets. The company's diverse offerings in...

Read more

JW Holdings Corporation, alongside its numerous subsidiaries, is a key player in the manufacturing and commercialization of pharmaceuticals and medical devices. Its operations span South Korea and global markets. The company's diverse offerings in...

JW Holdings Corporation Financial Statement Overview

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	1.01T	969.04B	887.71B	928.07B	864.54B	788.94B
Gross Profit	503.92B	472.93B	435.22B	446.16B	399.96B	344.18B
EBITDA	149.65B	207.32B	231.39B	128.53B	142.81B	96.34B
Net Income	84.47B	58.50B	62.62B	19.03B	22.15B	-2.78B
Balance Sheet
Total Assets	1.28T	1.23T	1.25T	1.18T	1.16T	1.07T
Cash, Cash Equivalents and Short-Term Investments	103.36B	90.79B	74.18B	154.50B	162.94B	104.35B
Total Debt	357.03B	359.62B	435.87B	554.59B	552.01B	487.84B
Total Liabilities	629.88B	611.60B	729.21B	827.51B	824.32B	760.96B
Stockholders Equity	289.97B	266.96B	229.54B	123.96B	106.99B	93.24B
Cash Flow
Free Cash Flow	168.97B	134.28B	62.19B	27.01B	34.32B	66.10B
Operating Cash Flow	208.02B	163.67B	97.89B	112.32B	104.43B	109.64B
Investing Cash Flow	-69.87B	-24.65B	17.71B	-69.23B	-107.02B	-7.64B
Financing Cash Flow	-104.58B	-111.53B	-141.40B	-29.08B	16.82B	-86.04B

JW Holdings Corporation Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: ―
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KR:096760, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 4074.50, equal to the 50-day MA of 4137.00, and equal to the 200-day MA of 3930.54, indicating a bearish trend. The MACD of -77.30 indicates Positive momentum. The RSI at 39.75 is Neutral, neither overbought nor oversold. The STOCH value of 22.69 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for KR:096760.

JW Holdings Corporation Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
096760	72 Outperform	₩271.92B	3.23	―	5.47%	10.18%	149.93%
001060	71 Outperform	₩560.29B	5.53	―	2.80%	10.50%	96.29%
000640	61 Neutral	₩581.17B	6.94	―	1.94%	10.06%	-3.74%
069620	61 Neutral	₩1.15T	5.90	―	0.60%	9.87%	160.28%
249420	60 Neutral	₩404.42B	8.96	―	1.56%	-0.65%	―
Sector *	55 Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
003000	50 Neutral	₩369.99B	64.89	―	3.33%	22.17%	-38.54%